FOURTH AMENDED AND RESTATED INCENTIVE COMPENSATION AGREEMENTIncentive Compensation Agreement • April 1st, 2024 • Immucell Corp /De/ • In vitro & in vivo diagnostic substances
This Fourth Amended and Restated Incentive Compensation Agreement, dated as of March 27, 2024, is by and between ImmuCell Corporation, a Delaware corporation (the “Company”) and Bobbi Jo Brockmann (the “Executive”), and replaces and supersedes in its entirety the Third Amended and Restated Incentive Compensation Agreement, dated as of March 28, 2023, between the Company and the Executive.
ImmuCell Corporation FIFTH AMENDED AND RESTATED INCENTIVE COMPENSATION AGREEMENTIncentive Compensation Agreement • April 1st, 2024 • Immucell Corp /De/ • In vitro & in vivo diagnostic substances
This Fifth Amended and Restated Incentive Compensation Agreement, dated as of March 27, 2024, is by and between ImmuCell Corporation, a Delaware corporation (the “Company”) and Elizabeth L. Williams (the “Executive”), and replaces and supersedes in its entirety the Fourth Amended and Restated Incentive Compensation Agreement, dated as of March 28, 2023, between the Company and the Executive.
